Misaligned Pharmacy Incentives in Value-Based Care

The authors discuss why pharmacy spending poses particular challenges for value-based care contracts between insurers and accountable care organizations, including the lack of transparency around rebates and the high cost of new, clinically effective therapies. Incorporating rebates and new drug approvals into pharmacy spending benchmarks, moving toward value-based formularies, and other strategies can help realign incentives.